Not yet recruiting
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
NCT07862751· Phase 2· Emory University· Source
Contact: Obi Ezennia
Recruiting
Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation
NCT07615049· Phase 3· SWOG Cancer Research Network· Source
Contact: Sibo Tian (principal investigator)
Not yet recruiting
Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer
NCT07860554· Phase 2· Emory University· Source
Contact: Jacob E. Berchuck, MD
Recruiting
CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
NCT07859722· Emory University· Source
Contact: Ardith Deshay
Recruiting
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
NCT07147231· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Olumide B. Gbolahan (principal investigator)
Recruiting
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
NCT07003295· Phase 2· National Cancer Institute (NCI)· Source
Contact: Jonathon B. Cohen (principal investigator)
Recruiting
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940· Phase 3· SWOG Cancer Research Network· Source
Contact: Olumide B. Gbolahan (principal investigator)
Recruiting
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Michael Lowe (principal investigator)
Recruiting
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07166406· Phase 3· NRG Oncology· Source
Contact: Soumon Rudra (principal investigator)
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· Phase 3· National Cancer Institute (NCI)· Source
Contact: Kristen Starbuck (principal investigator)
Recruiting
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
NCT07174570· Phase 2· Emory University· Source
Contact: Kathleen Coleman
Recruiting
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT06324240· Phase 1· Emory University· Source
Contact: Deborah Omoyege
Recruiting
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
NCT06524544· Phase 3· National Cancer Institute (NCI)· Source
Contact: Jacqueline T. Brown (principal investigator)
Recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
NCT07281430· National Cancer Institute (NCI)· Source
Contact: Lisa C. Flowers
Recruiting
Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment
NCT07112690· Emory University· Source
Contact: Jolinta Y. Lin
Recruiting
Addressing Health Literacy With a Tailored Survivorship Care Plan
NCT06674863· Emory University· Source
Contact: Sierra Williams
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source
Contact: Sarah Dilley (principal investigator)
Recruiting
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
NCT07155317· Phase 2· Emory University· Source
Contact: Tiffaney Roundtree
Recruiting
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT07001748· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source
Contact: Seth Concors (principal investigator)
Recruiting
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
NCT06492759· Phase 2· Emory University· Source
Contact: Ashley Lynn Trumbull
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· Phase 3· NRG Oncology· Source
Contact: Natalie A. Ridge (principal investigator)
Recruiting
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
NCT07101445· Phase 4· Emory University· Source
Contact: Joseph Rimando, MD
Recruiting
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
NCT07140679· Phase 2· Emory University· Source
Contact: Tyler Whitfield
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· NRG Oncology· Source
Contact: Pretesh R. Patel (principal investigator)
Recruiting
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
NCT06484062· Phase 1· National Cancer Institute (NCI)· Source
Contact: Michael J. Hochman (principal investigator)
Active, not recruiting
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT06732401· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
NCT06860594· Phase 1· National Cancer Institute (NCI)· Source
Contact: Kimberly Hoang (principal investigator)
Recruiting
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
NCT06724237· Phase 3· Eastern Cooperative Oncology Group· Source
Contact: Pamela B. Allen (principal investigator)
Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582· Phase 2· National Cancer Institute (NCI)· Source
Contact: Kamran Salari (principal investigator)
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Bradley C. Carthon (principal investigator)
Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· Phase 2/3· SWOG Cancer Research Network· Source
Contact: Jennifer W. Carlisle (principal investigator)
Recruiting
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
NCT06868433· Phase 1· Emory University· Source
Contact: Nilaab Meer
Recruiting
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
NCT06439836· Phase 1· National Cancer Institute (NCI)· Source
Contact: Jacqueline T. Brown (principal investigator)
Recruiting
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
NCT06731270· Phase 2· Emory University· Source
Contact: Jennifer W. Carlisle
Recruiting
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
NCT06287775· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Ticiana A. Leal (principal investigator)
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635· Phase 3· National Cancer Institute (NCI)· Source
Contact: Onkar V. Khullar (principal investigator)
Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Viraj Master (principal investigator)
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· Phase 3· NRG Oncology· Source
Contact: Jennifer M. Scalici (principal investigator)
Recruiting
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
NCT06760507· Emory University· Source
Contact: Yue Guan
Recruiting
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
NCT06650579· Phase 3· Emory University· Source
Contact: Sagar A. Patel, MD
Recruiting
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
NCT06006013· Phase 2· Emory University· Source
Contact: Wilena Session
Recruiting
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
NCT06132685· Phase 2· Emory University· Source
Contact: Agnes Harutyunyan
Recruiting
Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer
NCT06008730· Phase 2· Emory University· Source
Contact: Tegan VandenBosch
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Recruiting
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
NCT06636734· Phase 2· Emory University· Source
Contact: Ardith C. Deshay
Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682· Phase 2· SWOG Cancer Research Network· Source
Contact: Shirish M. Gadgeel (principal investigator)
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· National Cancer Institute (NCI)· Source
Contact: Kristie A. Blum (principal investigator)
Active, not recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)
NCT06611540· National Cancer Institute (NCI)· Source
Recruiting
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
NCT06328686· Early phase 1· Emory University· Source
Contact: Lisa Sudmeier, MD, PhD
Recruiting
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
NCT06423326· Phase 2· Georgetown University· Source
Contact: Kathleen M. Coleman
Showing 50 of 249.